Back to Results

HS LTE Study

Title Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa.
Therapeutic Area Hidradenitis Suppurativa
Principal Investigator David Rosmarin, MD
Min Age 18 Years
Gender All
Contact Nicole Dumont
617 636 7462
ndonovan1@tuftsmedicalcenter.org
More Information https://clinicaltrials.gov/ct2/show/NCT04179175

Overview

4 year long term extension study for subject who participated in previous HS study

Study Details

Inclusion Criteria

  • Subjects who complete the study treatment period (52 weeks) in the “Core studies” (CAIN457M2301 or CAIN457M2302)
  • Were on secukinumab treatment during the Treatment Period 2 of the core studies

Exclusion Criteria

  • Subjects not expected to benefit from participation in the extension study, as assessed by the subject and investigator

Study Requirements

23 visits for up to 4 years